Table 2

Patient outcomes and long-term toxicity (A) response and survival, (B) long-term toxicity

(A) Best responseMetastatic melanomaMetastatic renal cell
Surgical/SRS CRs95
No further treatment
Median follow-up10+ years10.5+ years
Range follow-up5+ to 15+ years5+ to 30+ years
Alive >10 years after IL-2 with no subsequent therapy32 patients27 patients
(B) Event# Patients
Hypothyroidism—requiring replacement medication (grade 2)5
Arthralgias/Arthritis (grade 1–2)6
Vitiligo (grade 1–2)3
Neuropathy (grade 2)1
Premature ventricular contractions (grade 1)1
Normal pressure hydrocephalus (grade 1)1
  • CR, complete response; DFS, disease-free survival; IL-2, interleukin-2; PR, partial response; SRS, stereotactic radiosurgery.